News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 236622

Friday, 09/25/2015 5:12:07 PM

Friday, September 25, 2015 5:12:07 PM

Post# of 347009
sorry north40000, that was supposed to be Carlton Johnson folded from Roswell Capital and was comparing it to Ayer Capital Management that had Jay V.

Jay Venkatesan's Linkedin page says owner of Ayer Capital.

He was with Bain Capital. HE'S A TURN AROUND GUY!!!!

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69039756



Interesting, Ayer Capital Management remains open but looks to be just closed to the "general public" according to their new website:
----
..
..
Ayer Capital Management, LP and its managed funds are not open for investment by members of the public. No offer of interests in such funds is being made or should be inferred. This web site is intended solely to provide general information about Ayer Capital Management, LP to our investors, and to financial counterparties, service providers, brokers, prospective employees, and to companies in which we invest.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93901144



Prior to joining Alpine BioVentures, Dr. Venkatesan was the executive vice president and general manager of Oncothyreon, Inc., which he joined after it was acquired by Alpine Biosciences, where he served as co-founder and CEO. Previously, Dr. Venkatesan was the founder, portfolio manager and managing director of Ayer Capital Management, a global healthcare long-short equity fund. Prior to that, he served as a director at Brookside Capital Partners, the hedge fund group affiliated with Bain Capital, where he co-managed healthcare investments and evaluated public and private investments in all healthcare subsectors. Earlier in his career, Dr. Venkatesan was involved in healthcare venture investing at Patricof & Co. Ventures (now Apax Partners) and consulting at McKinsey & Company.

In addition, Dr. Venkatesan currently serves on the Board of Directors of Lion Biotechnologies and AuraSense Therapeutics. He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.

http://www.businesswire.com/news/home/20150713005408/en/Dr.-Jay-Venkatesan-Joins-Alpine-BioVentures-Managing#.VgW2xZf76So



...North40000, as for your question in "where am I heading with this series of links.." ==> all I can say is I have not dozens, but hundreds upon hundreds of puzzle pieces and some pieces just don't fit just yet. This does not infer that there is anything wrong with everyone at Ayer Capital or everyone at Roswell Capital and certainly like there was not anything wrong with everyone at Peregrine Pharmaceuticals but we have CSM now with 2 lawsuits that were sealed up tight and closed to the public, 1 including the sabotage at Peregrine and there must have been a long line of reasons that led up to it all and I think we can all agree it did not start in Fargo ND

I, of course leave some puzzle pieces out of my posts because one has to be certain before making bold claims, so for now... I ask questions and wonder, which is #1 thing any longterm investor would do and us hitting rock $1 bottom again only makes me dig much deeper

We know the FDA does not want public attention on this and other Federal Authorities stepped into control that flow of information so when that happens..... its something much bigger that went on and some can't buy the world to stop that flow of information



"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y